CA3145824A1 - System for enhancing therapeutic compliance of the anti-cancer compound e7766 - Google Patents
System for enhancing therapeutic compliance of the anti-cancer compound e7766 Download PDFInfo
- Publication number
- CA3145824A1 CA3145824A1 CA3145824A CA3145824A CA3145824A1 CA 3145824 A1 CA3145824 A1 CA 3145824A1 CA 3145824 A CA3145824 A CA 3145824A CA 3145824 A CA3145824 A CA 3145824A CA 3145824 A1 CA3145824 A1 CA 3145824A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- patient
- inhibitor
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869389P | 2019-07-01 | 2019-07-01 | |
| US62/869,389 | 2019-07-01 | ||
| PCT/US2020/040515 WO2021003279A1 (en) | 2019-07-01 | 2020-07-01 | System for enhancing therapeutic compliance of the anti-cancer compound e7766 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3145824A1 true CA3145824A1 (en) | 2021-01-07 |
Family
ID=71895194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3145824A Pending CA3145824A1 (en) | 2019-07-01 | 2020-07-01 | System for enhancing therapeutic compliance of the anti-cancer compound e7766 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12564600B2 (https=) |
| EP (1) | EP3993809B1 (https=) |
| JP (1) | JP7704690B2 (https=) |
| KR (1) | KR20220029717A (https=) |
| CN (1) | CN114599374A (https=) |
| AU (1) | AU2020300543A1 (https=) |
| BR (1) | BR112021026876A2 (https=) |
| CA (1) | CA3145824A1 (https=) |
| MX (1) | MX2022000052A (https=) |
| WO (1) | WO2021003279A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024533394A (ja) | 2021-09-09 | 2024-09-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｓｔｉｎｇアゴニストのバイオマーカー及びその使用方法 |
| CN115512788B (zh) * | 2022-09-16 | 2023-08-08 | 山东大学 | 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2446893A1 (en) * | 2010-11-01 | 2012-05-02 | Bergen Teknologioverføring AS | Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters |
| JP2015516423A (ja) | 2012-05-07 | 2015-06-11 | ノバルティス アーゲー | アリスポリビルによる薬物動態の調節 |
| PL3265565T3 (pl) | 2015-03-04 | 2021-01-25 | Board Of Regents, The University Of Texas System | Sposoby leczenia nowotworu z hemizygotyczną utratą tp53 |
| JP2019512233A (ja) | 2016-03-10 | 2019-05-16 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 |
| US20200055883A1 (en) * | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| KR102512494B1 (ko) | 2017-06-30 | 2023-03-22 | 교와 가부시키가이샤 | 의약 |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
-
2020
- 2020-07-01 MX MX2022000052A patent/MX2022000052A/es unknown
- 2020-07-01 JP JP2021578078A patent/JP7704690B2/ja active Active
- 2020-07-01 KR KR1020227003441A patent/KR20220029717A/ko active Pending
- 2020-07-01 US US17/597,199 patent/US12564600B2/en active Active
- 2020-07-01 CA CA3145824A patent/CA3145824A1/en active Pending
- 2020-07-01 CN CN202080061033.0A patent/CN114599374A/zh active Pending
- 2020-07-01 EP EP20750022.4A patent/EP3993809B1/en active Active
- 2020-07-01 BR BR112021026876A patent/BR112021026876A2/pt unknown
- 2020-07-01 WO PCT/US2020/040515 patent/WO2021003279A1/en not_active Ceased
- 2020-07-01 AU AU2020300543A patent/AU2020300543A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020300543A1 (en) | 2022-02-24 |
| JP2022538898A (ja) | 2022-09-06 |
| CN114599374A (zh) | 2022-06-07 |
| MX2022000052A (es) | 2022-04-06 |
| EP3993809B1 (en) | 2024-10-09 |
| EP3993809A1 (en) | 2022-05-11 |
| BR112021026876A2 (pt) | 2022-02-22 |
| KR20220029717A (ko) | 2022-03-08 |
| US12564600B2 (en) | 2026-03-03 |
| WO2021003279A1 (en) | 2021-01-07 |
| US20220304982A1 (en) | 2022-09-29 |
| JP7704690B2 (ja) | 2025-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2609833C2 (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| AU2017315357B2 (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| HK1204998A1 (en) | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof | |
| EP3595725B1 (en) | Combination therapies for the treatment of breast cancer | |
| US12564600B2 (en) | System for enhancing therapeutic compliance of the anti-cancer compound E7766 | |
| JP7665700B2 (ja) | 肝細胞癌の治療のための併用療法 | |
| BR112014020008B1 (pt) | Composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação | |
| JP2022160654A (ja) | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ | |
| RU2820595C2 (ru) | Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766 | |
| US20260115161A1 (en) | 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies and neuropathic pain | |
| RU2787993C2 (ru) | Комбинированные терапии для лечения гепатоцеллюлярной карциномы | |
| WO2025218797A1 (zh) | 一种胶囊或固体制剂及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250130 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250203 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250505 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250627 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250627 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250715 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251114 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260112 |